<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01642563</url>
  </required_header>
  <id_info>
    <org_study_id>ISS-2007646931</org_study_id>
    <nct_id>NCT01642563</nct_id>
  </id_info>
  <brief_title>Italian Platelet Technology Assessment Study</brief_title>
  <acronym>IPTAS</acronym>
  <official_title>A Multi-center, Single-blind, Randomized, Parallel, Non Inferiority Study to Separately Investigate the Effect of Standard Platelets Versus Platelets Prepared With Two Commercial Procedures of Pathogen Reduction Technologies (PRT) on Bleeding Incidence and Severity in Thrombocytopenic Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Nazionale Sangue</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cerus Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Terumo BCT</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Nazionale Sangue</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Italian Platelet Technology Assessment Study (IPTAS) aims at comparing bleeding frequency and
      severity after transfusion of standard platelets versus platelets prepared with two
      commercial pathogen reduction technologies (PRT) and to perform a proteomic analysis of
      standard versus PRT platelets. The two technologies will be analyzed separately.

      Primary endpoint: incidence of bleeding of grade 2 or greater in recipients of PRT platelets
      versus incidence in recipients of control (standard) platelets.

      Secondary endpoints: time to the first grade 2 or greater bleeding event after the first
      study transfusion; proportion of transfusions given to treat breakthrough bleeding; number of
      days with grade 2 or greater bleeding during the period of platelet transfusion support;
      number of platelet units transfused and total dose of platelets transfused per day of
      thrombocytopenic platelet support; proportion of patients with acute transfusion reactions;
      post-transfusion platelet count increments

      Observational endpoints: frequency of human leukocyte antigen (HLA) alloimmunization,
      frequency of clinical refractoriness to platelet transfusion with demonstrated HLA
      alloimmunization, frequency of clinical refractoriness to platelet transfusion that is
      persistent during the period of platelet support in the absence of HLA or human platelet
      antigen (HPA) alloimmunization

      Patients will be evaluated for 4 weeks after randomization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When patient's platelet count, done in early morning every day, falls below 10000/microliter,
      physician in charge issues a platelet transfusion request to transfusion service. Transfusion
      service (which knows patient treatment arm) issues a PRT product or a standard product as
      indicated, typically within hours of request receipt; patient's physician identifies unit
      code and intended recipient's code and determines vital signs (pulse, blood pressure, body
      temp). Transfusion is started and completed in 30 min. Adverse reactions are monitored by
      ward personnel and once a day IPTAS local coordinator visits the ward, checks IPTAS patients'
      records, fills IPTAS forms, examines and interviews each enrolled patient and transfers
      filled forms to data coordinating center in Milan.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Patient enrolment below planned schedule
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of bleeding of grade 2 or greater in recipients of PRT platelets versus incidence in recipients of control (standard) platelets</measure>
    <time_frame>Within 4 weeks after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to the first grade 2 or greater bleeding event after the first study transfusion</measure>
    <time_frame>Within 4 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of transfusions given to treat breakthrough bleeding</measure>
    <time_frame>Within 4 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with grade 2 or greater bleeding during the period of platelet transfusion support</measure>
    <time_frame>Within 4 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of platelet units transfused per day of thrombocytopenic platelet support</measure>
    <time_frame>Within 4 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with acute transfusion reactions</measure>
    <time_frame>Within 4 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-transfusion platelet count increments</measure>
    <time_frame>Within 4 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of platelets transfused per day of thrombocytopenic platelet support</measure>
    <time_frame>Within 4 weeks after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">456</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Pathogen reduced platelets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard platelets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transfusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Platelet transfusion</intervention_name>
    <description>One dose of pathogen reduced platelets</description>
    <arm_group_label>Pathogen reduced platelets</arm_group_label>
    <other_name>Intercept</other_name>
    <other_name>Mirasol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Platelet transfusion</intervention_name>
    <description>One dose of standard platelets</description>
    <arm_group_label>Standard platelets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. adults (&gt; 18 years)

          2. a hematooncology diagnosis (includes patients newly diagnosed and previously
             diagnosed)

          3. expected to require 2 or more PLT transfusions in 4 weeks

          4. hospital admission (patients admitted to out-patient clinics will not be enrolled)

          5. chemotherapy, related and matched unrelated donor (MUD)transplant recipients

          6. recurrent auto-transplanted patients, requiring chemotherapy

          7. negative pregnancy test in female patients less than 60 years old

        Exclusion Criteria:

          1. presence of HLA class I abs on admission with PRA &gt;20%

          2. historical documented record of 2 or more 1 hour post-TX PLT corrected count
             increments &lt;5,000 per microliter

          3. previously included in IPTAS

          4. diagnosis of a solid tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Rebulla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Ca' Granda Ospedale Maggiore Policlinico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefania Frasca, Eng</last_name>
    <role>Study Director</role>
    <affiliation>Data Management</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Angelici, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fondazione Ca' Granda ospedale Maggiore Policlinico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Verona</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Proteomics Laboratory, Università della Tuscia</name>
      <address>
        <city>Viterbo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Rebulla P, Grazzini G, Liumbruno GM, Aprili G, Formisano S, Girelli G, Marconi M, Salvaneschi L, Strada P, Zolla L. Pathogen inactivated platelets and prevention of immunological adverse reactions: the Italian Platelet Technology Assessment Study (IPTAS). Blood Transfus 2009;7 Suppl 1:s19-s21. DOI 10.2450/2009.0013-09.</citation>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2012</study_first_submitted>
  <study_first_submitted_qc>July 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2012</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platelet transfusion</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Transfusion transmissible infections</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Allogeneic hemopoietic stem cell transplant</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

